Lobe Sciences Ltd.
LOBEF · OTC
8/31/2024 | 8/31/2023 | 8/31/2022 | 8/31/2021 | |
|---|---|---|---|---|
| Market Cap | $3 | $2 | $1 | $1 |
| - Cash | $0 | $0 | $1 | $1 |
| + Debt | $2 | $0 | $0 | $0 |
| Enterprise Value | $4 | $3 | -$0 | -$0 |
| Revenue | $0 | $1 | $0 | $0 |
| % Growth | -83.8% | – | – | – |
| Gross Profit | $0 | $1 | -$0 | $0 |
| % Margin | 98.7% | 97.1% | – | – |
| EBITDA | -$4 | -$4 | -$4 | -$6 |
| % Margin | -3,021.9% | -525.9% | – | – |
| Net Income | -$4 | -$5 | -$12 | -$10 |
| % Margin | -3,245.8% | -560% | – | – |
| EPS Diluted | -0.036 | -0.045 | -0.32 | -0.3 |
| % Growth | 19.7% | 85.9% | -6.7% | – |
| Operating Cash Flow | -$0 | -$2 | -$3 | -$5 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$2 | -$3 | -$5 |